LabCorp, a North Carolina-based healthcare diagnostics company, and Shandong XuanZhu Pharma, the wholly-owned subsidiary for innovative drug R&D of Sihuan Pharmaceutical, have inked a long-term partnership with Covance Drug Development (part of LabCorp) to support the global development of Sihuan’s drug candidate pipeline.
Covance will support the preclinical and clinical development of Sihuan’s drug candidate pipeline, which includes new molecules that address unmet needs in therapeutic areas including cardiovascular, metabolic, infectious disease, oncology and urology. This innovative model will bring compounds through the product life cycle from early to late stages, maximizing the value of drug development solutions and supporting greater efforts to bring drugs to market in China, the Asia Pacific region and globally.
Specifically, Covance will provide Sihuan with global drug development and regulatory experience, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as IND applications and NDA in China and internationally. As these drug candidates enter development, Covance’s specialized therapeutic area knowledge and its fully standardized global systems will enable more efficient development and advancement of these molecules.
The partnership will enable Sihuan and Covance to work in collaboration to implement a customized program to bring best-in-class solutions to market.